Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
06 Giugno 2023 - 2:00PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
the appointment of Marc Besman Ph.D., as Senior Vice President of
Regulatory Affairs and Clinical Quality Assurance. Dr. Besman
will be responsible for developing, implementing, and advancing
global regulatory strategies for Kronos Bio’s portfolio. He will
also ensure that the Company upholds the highest levels of clinical
quality compliance.
“As we progress our clinical programs, regulatory strategy will
be critical for Kronos Bio’s continued success,” said Norbert
Bischofberger, Ph.D., president and chief executive officer of
Kronos Bio. “Marc has extensive drug development experience in
oncology, and he’s worked closely with global health authorities to
bring important drugs to patients in need. I’m confident that Marc
will make meaningful contributions to Kronos Bio as we plan for the
future of KB-0742 and lanraplenib as well as our discovery
programs.”
Dr. Besman joins Kronos Bio from Coherus BioSciences where he
served as Senior Vice President of Regulatory Affairs. While at
Coherus BioSciences, he built out the regulatory affairs function
and helped to advance the Company’s oncology development programs.
Previously, including at CytomX Therapeutics, Inc., Allergan, CTI
Seattle and Baxter BioSciences, Dr. Besman held a series of
leadership roles in regulatory affairs, development, and program
management.
Dr. Besman received a B.Sc. Honours in Chemistry with
Biochemistry from the University of Southampton (UK) and a M.Phil.
and Ph.D. in Biochemistry from Yale University and he pursued a
post-doctoral fellowship at the City of Hope, California.
About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical company that
is advancing two investigational compounds in clinical trials for
patients with cancer. The company is developing the CDK9 inhibitor
KB-0742 as a treatment for MYC-amplified solid tumors and other
transcriptionally addicted solid tumors and lanraplenib, a
next-generation SYK inhibitor, for patients with FLT3-mutated acute
myeloid leukemia. The company’s scientific focus is on developing
medicines that target the deregulated transcription that is the
hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and
has a research facility in Cambridge, Mass. For more information,
visit www.kronosbio.com or follow the company on LinkedIn.
Contacts for Investors and Media:
Company Contact:Sarah ConnorsVice President of
Investor Relations and Corporate CommunicationsKronos
Bio857-290-7305sconnors@kronosbio.com
Agency Contact:Leo VartorellaArgot Partners
212-600-1902kronosbio@argotpartners.com
Grafico Azioni Kronos Bio (NASDAQ:KRON)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Kronos Bio (NASDAQ:KRON)
Storico
Da Giu 2023 a Giu 2024